235 related articles for article (PubMed ID: 34390562)
1. [Clinical pharmacokinetics and pharmaceutical forms of long-acting injectable antipsychotics].
Kyziridis TC
Psychiatriki; 2022 Jun; 33(2):139-148. PubMed ID: 34390562
[TBL] [Abstract][Full Text] [Related]
2. Letter to the Editor: Rethinking The Cost Of Antipsychotic Treatment: The Average Cost Of The Drugs Used In Turkey In 2020.
Yıldız M; Osman E
Turk Psikiyatri Derg; 2022; 33(2):146-148. PubMed ID: 35730516
[TBL] [Abstract][Full Text] [Related]
3. Cost Effectiveness of Paliperidone Long-Acting Injectable Versus Other Antipsychotics for the Maintenance Treatment of Schizophrenia in France.
Druais S; Doutriaux A; Cognet M; Godet A; Lançon C; Levy P; Samalin L; Guillon P
Pharmacoeconomics; 2016 Apr; 34(4):363-91. PubMed ID: 26883132
[TBL] [Abstract][Full Text] [Related]
4. Maintenance Treatment With Long-Acting Injectable Antipsychotics for People With Nonaffective Psychoses: A Network Meta-Analysis.
Ostuzzi G; Bertolini F; Del Giovane C; Tedeschi F; Bovo C; Gastaldon C; Nosé M; Ogheri F; Papola D; Purgato M; Turrini G; Correll CU; Barbui C
Am J Psychiatry; 2021 May; 178(5):424-436. PubMed ID: 33596679
[TBL] [Abstract][Full Text] [Related]
5. Treatment Patterns, Health Care Resource Utilization, and Spending in Medicaid Beneficiaries Initiating Second-generation Long-acting Injectable Agents Versus Oral Atypical Antipsychotics.
Pilon D; Tandon N; Lafeuille MH; Kamstra R; Emond B; Lefebvre P; Joshi K
Clin Ther; 2017 Oct; 39(10):1972-1985.e2. PubMed ID: 28919292
[TBL] [Abstract][Full Text] [Related]
6. Comparative effectiveness of long-acting injectable antipsychotics in patients with schizophrenia in Japan.
Okada Y; Inada K; Akazawa M
Schizophr Res; 2023 Feb; 252():300-308. PubMed ID: 36706475
[TBL] [Abstract][Full Text] [Related]
7. Long-Acting Injectable Second-Generation Antipsychotics vs Placebo and Their Oral Formulations in Acute Schizophrenia: A Systematic Review and Meta-Analysis of Randomized-Controlled-Trials.
Wang D; Schneider-Thoma J; Siafis S; Burschinski A; Dong S; Wu H; Zhu Y; Davis JM; Priller J; Leucht S
Schizophr Bull; 2024 Jan; 50(1):132-144. PubMed ID: 37350486
[TBL] [Abstract][Full Text] [Related]
8. [Cost-effectiveness analysis of schizophrenic patient care settings: impact of an atypical antipsychotic under long-acting injection formulation].
Llorca PM; Miadi-Fargier H; Lançon C; Jasso Mosqueda G; Casadebaig F; Philippe A; Guillon P; Mehnert A; Omnès LF; Chicoye A; Durand-Zaleski I
Encephale; 2005; 31(2):235-46. PubMed ID: 15959450
[TBL] [Abstract][Full Text] [Related]
9. Adverse effects associated with second-generation antipsychotic long-acting injection treatment: a comprehensive systematic review.
Gentile S
Pharmacotherapy; 2013 Oct; 33(10):1087-106. PubMed ID: 23776129
[TBL] [Abstract][Full Text] [Related]
10. Long-Acting Injectable Second-Generation Antipsychotics: An Update and Comparison Between Agents.
Jann MW; Penzak SR
CNS Drugs; 2018 Mar; 32(3):241-257. PubMed ID: 29569082
[TBL] [Abstract][Full Text] [Related]
11. Long-acting injectable antipsychotics and the development of postinjection delirium/sedation syndrome (PDSS).
Novakovic V; Adel T; Peselow E; Lindenmayer JP
Clin Neuropharmacol; 2013; 36(2):59-62. PubMed ID: 23503549
[TBL] [Abstract][Full Text] [Related]
12. Switching from oral atypical antipsychotic monotherapy to paliperidone palmitate once-monthly in non-acute patients with schizophrenia: A prospective, open-label, interventional study.
Schreiner A; Caspi A; Bergmans P; Cherubin P; Keim S; Lara E; Pinchuk I; Schuepbach D; Suleman S; Hargarter L
Psychopharmacology (Berl); 2017 Jan; 234(1):3-13. PubMed ID: 27815602
[TBL] [Abstract][Full Text] [Related]
13. Going the distance: reviewing antipsychotic depot or long-acting injectable treatments in Australasia.
Theodoros T; Taylor M; Huang HC; Wang N; Motamarri B
Australas Psychiatry; 2018 Jun; 26(3):303-306. PubMed ID: 29457473
[TBL] [Abstract][Full Text] [Related]
14. Switching to long-acting injectable antipsychotics: pharmacological considerations and practical approaches.
Højlund M; Correll CU
Expert Opin Pharmacother; 2023; 24(13):1463-1489. PubMed ID: 37345508
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of long acting injectable atypical antipsychotics: a review.
De Berardis D; Marini S; Carano A; Lang AP; Cavuto M; Piersanti M; Fornaro M; Perna G; Valchera A; Mazza M; Iasevoli F; Martinotti G; Di Giannantonio M
Curr Clin Pharmacol; 2013 Aug; 8(3):256-64. PubMed ID: 23343445
[TBL] [Abstract][Full Text] [Related]
16. Real-world effectiveness of long-acting injectable antipsychotic treatments in a nationwide cohort of 12,373 patients with schizophrenia-spectrum disorders.
Boyer L; Falissard B; Nuss P; Collin C; Duret S; Rabbani M; De Chefdebien I; Tonelli I; Llorca PM; Fond G
Mol Psychiatry; 2023 Sep; 28(9):3709-3716. PubMed ID: 37479781
[TBL] [Abstract][Full Text] [Related]
17. Healthcare resource utilization of second-generation long-acting injectable antipsychotics in schizophrenia: risperidone versus paliperidone palmitate.
Joshi K; Pan X; Wang R; Yang E; Benson C
Curr Med Res Opin; 2016 Nov; 32(11):1873-1881. PubMed ID: 27479694
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetic Characteristics of Long-Acting Injectable Antipsychotics for Schizophrenia: An Overview.
Correll CU; Kim E; Sliwa JK; Hamm W; Gopal S; Mathews M; Venkatasubramanian R; Saklad SR
CNS Drugs; 2021 Jan; 35(1):39-59. PubMed ID: 33507525
[TBL] [Abstract][Full Text] [Related]
19. Association between discontinuation due to withdrawal of consent and use of long-acting injectable antipsychotics: A meta-analysis of randomized trials for schizophrenia.
Kishi T; Sakuma K; Okuya M; Iwata N
J Psychiatr Res; 2021 Jan; 132():144-150. PubMed ID: 33096355
[TBL] [Abstract][Full Text] [Related]
20. Clozapine augmentation with long-acting antipsychotic injections: A case series and systematic review.
Oloyede E; Dima A; Taylor D; Cheung H; Dzahini O; Shergill S; Whiskey E
Acta Psychiatr Scand; 2023 Dec; 148(6):538-552. PubMed ID: 37899506
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
